While the investment banking world does its best to sing the virtues and likelihood of biotech consolidation, the industry isn't paying attention. Indeed, perhaps the most interesting aspect of J&J's acquisition of Scios isn't the fact that J&J outbid the competition, but just how little competition it had to outbid for one of the very few clearly successful product-oriented biotechs.
While the investment banking world does its best to sing the
virtues and likelihood of biotech consolidation, the industry isn't
paying attention.
Indeed, perhaps the most interesting aspect of Johnson & Johnson 's acquisition of Scios Inc. [See Deal] isn't...